Depigmentation

Incyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of Opzelura® (Ruxolitinib) Cream in Vitiligo

Retrieved on: 
Saturday, March 18, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Inflammation, Week, The New England Journal of Medicine, Autoimmunity, American Academy, Depigmentation, Patient, AAD, BID, American Academy of Dermatology, Vitiligo, LTE, Skin, Safety, Pharmaceutical industry

The 104-week long-term extension (LTE) data build on the positive 52-week TRuE-V1 and TRuE-V2 results previously announced and published in The New England Journal of Medicine.

Key Points: 
  • The 104-week long-term extension (LTE) data build on the positive 52-week TRuE-V1 and TRuE-V2 results previously announced and published in The New England Journal of Medicine.
  • “The results presented today at AAD are significant because they provide important long-term efficacy and safety data for nonsegmental vitiligo patients treated with Opzelura,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & Autoimmunity, Incyte.
  • Approximately 29% of patients randomized to the withdrawal arm (i.e., applying vehicle cream) relapsed (
  • “Vitiligo is a chronic condition and these results demonstrate the long-term potential of this medical treatment for people with vitiligo who are interested in repigmentation.”

Incyte Announces the Validation of the European Marketing Authorization Application for Ruxolitinib Cream in Vitiligo

Retrieved on: 
Thursday, October 28, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, Safety, MAA, European Academy of Allergy and Clinical Immunology, Research, Vitiligo, Disease, BID, Knowledge, Annual report, Depigmentation, European Medicines Agency, Melanocyte, EMA, Security (finance), U.S. Securities and Exchange Commission, Patient, FDA, INT, Food, Face, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Life, Atopic dermatitis, Marketing, Company, Congress, Body surface area, VNS, COVID-19, Inflammation, Skin, AD, JAK, Program, Hidradenitis suppurativa, Solution, Classification, Therapy, BSA, Population, Prevalence, Week, Vaccine, Pharmaceutical industry, Cosmetics, TRuE-V, Ruxolitinib Cream, Incyte Dermatology, Incyte, TRUE-V, RUXOLITINIB CREAM, INCYTE DERMATOLOGY, INCYTE

Incyte (Nasdaq:INCY) today announced the validation of the European Marketing Authorization Application (MAA) for ruxolitinib cream, a topical JAK inhibitor, as a potential treatment for adolescents and adults (age >12 years) with non-segmental vitiligo with facial involvement.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced the validation of the European Marketing Authorization Application (MAA) for ruxolitinib cream, a topical JAK inhibitor, as a potential treatment for adolescents and adults (age >12 years) with non-segmental vitiligo with facial involvement.
  • In the TRuE-V studies, patients using ruxolitinib cream did not report clinically significant application site reactions, and the overall safety profile was consistent with previous study data.
  • Ruxolitinib cream is an investigational novel cream formulation of Incytes selective JAK1/JAK2 inhibitor ruxolitinib.
  • Incyte has worldwide rights for the development and commercialization of ruxolitinib cream, marketed in the United States as Opzelura.

BIO10 FORTE By Lullage, an Authentic Revolution in Dark Spots Correctors

Retrieved on: 
Wednesday, September 1, 2021
Other Health, Men, General Health, Online Retail, Pharmaceutical, Consumer, Convenience Store, Cosmetics, Retail, Other Consumer, Women, Health, Aurora, Absorption, Face, Vitamin C, Multimedia, Neck, Woman, Depigmentation, R, Skin, Cosmetics

With a strong presence in Europe, Asia and the Americas, Lullage is growing stronger in the US market with its own branch in Florida.

Key Points: 
  • With a strong presence in Europe, Asia and the Americas, Lullage is growing stronger in the US market with its own branch in Florida.
  • View the full release here: https://www.businesswire.com/news/home/20210901005606/en/
    bio10 forte brings to life a real revolution in dark spots solutions.
  • bio10 forte, gentle on the skin, is an intensive corrector for all types of dark spots (age-related, solar, hormonal, post-inflammatory).
  • Dark spots are usually caused by sun exposure, hormonal changes, or medications.

Legal-Bay Lawsuit Funding Announces Influx of Just for Men Litigation Filings

Retrieved on: 
Wednesday, September 1, 2021
PPD, Skin, Man, HERE, Combe Incorporated, Injury, Allergy, CEO, Just, Lists of action films, Depigmentation, Vitiligo, Cosmetics, Pharmaceutical industry

WHITE PLAINS, N.Y., Sept. 1, 2021 /PRNewswire/ -- Legal-Bay, The premiere Presettlement Funding Company, reports a recent uptick in filings against Combe Incorporated, the company behind Just for Men hair dyes.

Key Points: 
  • WHITE PLAINS, N.Y., Sept. 1, 2021 /PRNewswire/ -- Legal-Bay, The premiere Presettlement Funding Company, reports a recent uptick in filings against Combe Incorporated, the company behind Just for Men hair dyes.
  • Individual lawsuits have been filed in places like Louisiana, Florida, and North Carolina, while a class-action suit has been filed in Missouri.
  • Legal-Bay's pre-settlement funding programs are designed to provide immediate cash in advance of a plaintiff's anticipated monetary award.
  • The non-recourse funding is risk-free, as the money doesn't need to be repaid should the recipient lose their case.